AstraZeneca

Moventig® approved in the European Union for opioid-induced constipation

9 December 2014 08:02

First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives

Jury verdict favours AstraZeneca in Nexium antitrust litigation

5 December 2014 18:06

AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
AstraZeneca is pleased with the jury’s verdict. The Company has always maintained that the plaintiffs’ alle

New Drug Application for IRESSA accepted by US Food and Drug Administration

2 December 2014 08:03

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test. The P

AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease

1 December 2014 08:03

AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.

Medimmune completes acquisition of Definiens

26 November 2014 08:16

AstraZeneca today announced that MedImmune, its global biologics research and development arm, completed its acquisition of Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue.

Amgen and AstraZeneca announce positive results from third and final pivotal phase III study of brodalumab

25 November 2014 22:09

Study met all primary endpoints against Stelara® (ustekinumab)
and placebo
Three pivotal studies form the basis for global regulatory filings, planned for 2015
AstraZeneca and Amgen today announced that AMAGINE-2TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when c

Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease

24 November 2014 08:03

AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

AstraZeneca på rätt spår att leverera hållbar tillväxt och värde genom innovation

18 November 2014 08:03

Forskningsportföljen i sen fas ligger långt före tidsplanen tack vare ökad produktivitet inom R&D, accelererade program och en målinriktad affärsutveckling; 14 potentiella nya läkemedel finns i fas III eller är under registrering; vi har potential för 14–16 ansökningar och 8–10 godkännanden under 2015–2016. En branschledande immuno-onkologiportfölj med 13 pågående kombinationsprövningar och 16

AstraZeneca announces initiation of development programme for BRILINTA® reversal agent

13 November 2014 08:02

Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014

Världsdiabetesdagen. Många svenskar med typ-2 diabetes får inte tillgång till nya diabetesläkemedel

12 November 2014 09:01

Världsdiabetesdagen 14 november: Sverige har hamnat på efterkälken när det gäller användning av nya diabetesläkemedel och ligger exempelvis långt efter Finland och Danmark1. En undersökning med över 2 000 svenskar med typ 2-diabetes visar dessutom att användningen av nya diabetesläkemedel varierar starkt beroende på var i Sverige man bor2. Kunskapen om olika diabetesbehandlingar är låg 2.

Amgen and AstraZeneca announce positive results from second pivotal phase III study of brodalumab in patients with moderate-to-severe plaque psoriasis

11 November 2014 22:18

Brodalumab meets all primary and all key secondary endpoints Meets primary endpoint of superiority to Stelara® (ustekinumab) in achieving total skin clearance (PASI 100) Meets co-primary endpoints against placebo

AstraZeneca to present new data from its growing inflammation and autoimmunity pipeline at American College of Rheumatology 2014 annual meeting

11 November 2014 08:05

AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from the company’s growing inflammation and autoimmunity portfolio at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts, 14-19 November 2014.
More than 15 abstracts will be featured at the ACR meeting, providing evidence of the depth and continued progress

Nyhetsarkiv